Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting

Abstract

Abstract Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% ORR when combined with decitabine/cedazuridine and venetoclax. These findings underscore the potential of menin inhibitors in transforming AML treatment, particularly in genetically defined subgroups, offering hope for improved patient outcomes. Ongoing studies, like KOMET-008, further explore the synergistic potential of menin inhibitors in combination regimens, shaping future AML management strategies.

Keywords

• Menin inhibitors
• Acute myeloid leukemia
• Revumenib
• Ziftomenib
• Clinical trials